Cassels retires as chief administrator at Winship

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Diane Cassels will retire as chief administrator of Winship Cancer Institute of Emory University after 24 years of service, having served in a number roles including including chief department administrator for radiation oncology and administrator for the Emory Clinic’s Section of Radiation Oncology and chief operating officer at the Emory Children’s Center and Department of Pediatrics.

Cassels was named Winship’s executive administrator in 2010, transitioning to Winship’s chief administrative officer in January 2016.

During her tenure, Winship doubled its clinical footprint and clinical patient volume, expanded its membership from 268 to 434, and expanded the infrastructure for the conduct of clinical trials and laboratory research.

YOU MAY BE INTERESTED IN

For nearly 25 years, business executive Lou Weisbach and urologist Richard J. Boxer have argued that finding the money to finance the cures for devastating diseases is not as difficult as it appears. To start finding the cures, the U.S. Department of the Treasury needs to issue some bonds—$750 billion worth. Next, you hire CEOs—one...

There is general agreement that the United States spends too much on health care, especially on pharmaceuticals.  But what we spend on drugs is not simply a function of price. If eggs double in price, people can simply cut the number of eggs they eat in half.  Simply stated, cost is the product of (price per unit times the number of units purchased). 
What did President Richard M. Nixon and Senator Edward M. Kennedy have in common? They each played a pivotal role in the passage of the National Cancer Act signed by Nixon on Dec. 23, 1971. The NCA established the National Cancer Program authorizing the initial investment in the NCI-designated Cancer Centers Program. 
When I first proposed targeting PCNA (proliferating cell nuclear antigen) as a therapeutic approach, the response I got was: “No one will ever make a drug against PCNA. It’s undruggable.” The protein lacks enzymatic activity, has a disordered region, and binds to over 200 other proteins within the cell. From a traditional drug development perspective, these characteristics made PCNA an impossible target.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login